Global market of dietary supplement is welcoming a rising star GLYMATE

Food and Healthcare Press Releases Monday August 19, 2019 08:00
BREA, California--19 Aug--PRNewswire/InfoQuest

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product, which is available to consumers worldwide.

Glymate(TM) is an intense cellular regeneration dietary supplement that benefits the human body at multiple levels, and its patented key ingredient differentiates itself from other products. Our cellular regeneration technology promotes healthy insulin sensitivity and production which helps to break down glucose from food and transfer to energy*. When Glymate(TM) is consumed consistently, it helps our body energized and promotes bodyweight loss*. It is currently available through the company website and Amazon; we are also working with distributors for greater market access worldwide.

Today, there are more than 400 millions of people in the world are suffering from diabetes and the number of people who have high sugar blood level to prediabetes condition is much greater. "It's urgent that we take swift action to effectively treat and prevent this serious disease," a statement from the CDC reads. Glymate has dedicated years of research and numerous trials specifically to help the urgent needs of humans to address and prevent the seriousness of this problem. Glymate(TM) uses only all-natural ingredients, it is dairy-free, soy-free, gluten-free, wheat-free, no sugar, no preservatives and it's manufactured by Robinson in California. Its uniquely formulated soft gel with its proprietary patented regeneration technology is designed to help improve and balance blood sugar, cholesterol, and triglyceride levels by promoting healthy lipid metabolism*. It is carefully blended to increase the solubility and absorbency of the active ingredients. Glymate(TM)'s key ingredient affects the body at the molecular level and has a variety of functions inside cells*.

About Glymate(TM) Corp.

The Glymate(TM) Corp. is a privately held company, a global leader in health and wellness backed by a proven track record in its patented key ingredient. As a marketer and online seller of dietary supplements, we are committed to supporting consumers' wellness needs through high-quality product backed by science.

To learn more about Glymate(TM), please visit https://www.glymateusa.com. Follow Glymate(TM) on Instagram now at @glymate_usa.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Logo - https://mma.prnewswire.com/media/959709/Glymate_Logo.jpg

Latest Press Release

New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

BAVENCIO(R) (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX(R) (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for first-line...

CHMP Adopts Positive Opinion for BAVENCIO(R) (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Merck and...

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

Related Topics